UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman

A securities class action has been filed against UroGen Pharma (URGN) on behalf of investors who purchased shares between July 27, 2023, and May 15, 2025, alleging the company made misleading statements regarding its communications with the FDA about its UGN-102 drug application; specifically, the lawsuit claims UroGen downplayed the FDA's concerns about the single-arm trial design. The suit follows a drop in UroGen's stock price after the FDA released a briefing document highlighting concerns about the trial's design and efficacy data, ultimately leading to an ODAC vote against the drug's risk/profile.

Analysis

UroGen Pharma Ltd. (NASDAQ: URGN) is facing a securities class action lawsuit (Cockrell v. UroGen Pharma Ltd. et al., No. 3:25-cv-06088) for the period between July 27, 2023, and May 15, 2025. The litigation alleges that UroGen made materially false and misleading statements concerning its communications with the FDA regarding the New Drug Application (NDA) for UGN-102, a therapy for low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Specifically, the complaint claims UroGen failed to disclose that its pivotal single-arm ENVISION trial was not adequately designed to demonstrate UGN-102's effectiveness, that it would struggle to attribute duration of response to the drug, and that it disregarded FDA warnings about the trial design, thereby creating a substantial risk of non-approval. This situation culminated on May 16, 2025, when an FDA briefing document, preceding an Oncologic Drugs Advisory Committee (ODAC) meeting, revealed the FDA had repeatedly advised UroGen to conduct a randomized trial due to concerns about interpreting efficacy and safety from a single-arm study. The document noted difficulties in interpreting complete response and duration of response endpoints from the ENVISION trial. Subsequently, on May 21, 2025, UroGen announced ODAC voted 5 to 4 against the risk/benefit profile of UGN-102, with one member citing the lack of a randomized trial and limited long-term follow-up. These events triggered a sharp decline in UroGen's share price. The overall sentiment surrounding this news is strongly negative (-0.8) with a notable market impact score (0.6), and the per-ticker sentiment for URGN is exceptionally low at -0.9, underscoring the severe investor concern and fallout from these regulatory and legal challenges.

Key Decisions for Investors

• Investors who acquired UroGen securities between July 27, 2023, and May 15, 2025, and incurred substantial losses should consider contacting Hagens Berman before the July 28, 2025, lead plaintiff deadline to evaluate their potential participation in the class action lawsuit.
• Given the FDA's explicitly stated concerns regarding the UGN-102 trial design and the negative ODAC vote, the pathway to approval for UGN-102 appears highly uncertain, warranting extreme caution for current and prospective investors.
• Monitor closely any further communications from UroGen regarding its regulatory strategy for UGN-102, potential new clinical trial requirements, and developments in the securities class action, as these will be critical drivers of future stock performance and viability.
• The confluence of a negative ODAC recommendation and ongoing securities litigation introduces significant downside risk and potential for sustained stock price volatility; thus, a thorough risk assessment is crucial before making any investment decisions regarding URGN.